Cancer Drugs

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 Johnson & Johnson will acquire cancer-treatment developer AmbrxBiopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the…

Shoddy conditions at factories in India have sickened Americans and stoked a chemotherapy-drug shortage for cancer patients, raising calls for a more-resilient generic-drug supply. Shoddy conditions at factories in India have sickened Americans and stoked a chemotherapy-drug shortage for cancer patients, raising calls for a more-resilient generic-drug supply. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In…

HealthHealth emergency’s end means independent cancer doctors can’t send prescriptions directly to their Medicare patients HealthHealth emergency’s end means independent cancer doctors can’t send prescriptions directly to their Medicare patients FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all…

The drugmaker filed a lawsuit saying Medicare’s drug-price negotiation program violates the company’s constitutional rights. The drugmaker filed a lawsuit saying Medicare’s drug-price negotiation program violates the company’s constitutional rights. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all…

HealthIn temporary move, Chinese drugmaker will be able to ship its cisplatin chemotherapy even though it hasn’t been FDA approved HealthIn temporary move, Chinese drugmaker will be able to ship its cisplatin chemotherapy even though it hasn’t been FDA approved FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful…

With modern technologies, the field of medical science has also advanced. Doctors and scientists have discovered new treatment methods to cure several deadly…

Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire, the company said Wednesday. Chief Commercialization Officer Christopher Boerner will take the helm when Dr. Caforio leaves his position Nov. 1, the company said. Dr. Caforio will remain executive chairman of the drugmaker. Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire, the company said Wednesday. Chief Commercialization Officer Christopher Boerner will take the…

The gold rush from pioneering cancer immunotherapy Keytruda is about to run out for Merck & Co.  Keytruda, one of the world’s top-selling drugs, powered its maker for the past decade. The therapy’s annual sales neared $21 billion last year, about a third of Merck’s revenue. Yet a drop in sales looms after Keytruda’s main patent expires in 2028. The gold rush from pioneering cancer immunotherapy Keytruda is about to run out for Merck & Co.  Keytruda, one of the…

Moderna Inc.’s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system.  About 79% of high-risk melanoma patients who got Moderna’s personalized vaccine and Merck & Co.’s immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, researchers said Sunday. The 157-person trial…

U.S. health officials released the first list of drugs paid for by the government’s Medicare insurance program whose prices went up more than the rate of inflation and will face a penalty under a new federal law.The Centers for Medicare and Medicaid Services on Wednesday named 27 drugs that had the large price increases, including  rheumatoid-arthritis treatment Humira from AbbVie Inc. and Yescarta lymphoma therapy from Gilead Sciences Inc., and will face the…